Q1 Earnings Estimate for OmniAb Issued By Leerink Partnrs

OmniAb, Inc. (NASDAQ:OABI) – Equities research analysts at Leerink Partnrs issued their Q1 2026 earnings estimates for shares of OmniAb in a research note issued on Thursday, April 17th. Leerink Partnrs analyst P. Souda expects that the company will earn ($0.16) per share for the quarter. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. Leerink Partnrs also issued estimates for OmniAb’s Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.15) EPS and Q4 2026 earnings at ($0.15) EPS.

Other analysts also recently issued reports about the company. Benchmark lowered their price target on OmniAb from $8.00 to $6.00 and set a “buy” rating for the company in a report on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of OmniAb in a report on Wednesday, March 19th. Finally, Royal Bank of Canada decreased their price target on OmniAb from $7.00 to $4.00 and set an “outperform” rating for the company in a report on Thursday, March 27th.

OmniAb Price Performance

NASDAQ OABI opened at $1.79 on Friday. OmniAb has a 1-year low of $1.70 and a 1-year high of $4.96. The business’s 50-day simple moving average is $2.85 and its 200-day simple moving average is $3.46. The firm has a market capitalization of $218.62 million, a P/E ratio of -2.89 and a beta of 0.06.

OmniAb (NASDAQ:OABI) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. The business had revenue of $10.80 million for the quarter, compared to the consensus estimate of $10.13 million. OmniAb had a negative return on equity of 20.97% and a negative net margin of 308.78%. During the same period in the prior year, the business earned ($0.14) earnings per share.

Institutional Trading of OmniAb

A number of hedge funds have recently bought and sold shares of OABI. Hsbc Holdings PLC acquired a new position in OmniAb during the fourth quarter valued at $38,000. Rangeley Capital LLC acquired a new stake in shares of OmniAb during the fourth quarter worth approximately $41,000. Choreo LLC acquired a new stake in shares of OmniAb during the fourth quarter worth approximately $41,000. KLP Kapitalforvaltning AS purchased a new position in OmniAb during the fourth quarter valued at approximately $49,000. Finally, Sherbrooke Park Advisers LLC increased its stake in OmniAb by 53.5% in the 4th quarter. Sherbrooke Park Advisers LLC now owns 17,226 shares of the company’s stock valued at $61,000 after buying an additional 6,001 shares during the period. 72.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at OmniAb

In other news, CEO Matthew W. Foehr sold 41,811 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $135,467.64. Following the completion of the transaction, the chief executive officer now owns 3,749,639 shares in the company, valued at approximately $12,148,830.36. This represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kurt A. Gustafson sold 7,255 shares of the company’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $3.67, for a total transaction of $26,625.85. Following the completion of the sale, the chief financial officer now directly owns 206,211 shares of the company’s stock, valued at $756,794.37. The trade was a 3.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 150,811 shares of company stock worth $458,129 over the last quarter. 8.60% of the stock is owned by corporate insiders.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.